Profile

2001

Established in Shanghai

The first

Category I biological drug approved in China to have received funding under the 11th Five-Year Plan National Science and Technology Major Project — Major Innovative Drug Development.(PUK)

13

A product portfolio of 13 biological assets

Leading

Perfusion culture technology platform for mammalian cells

Commercialization
platforms integrating

R&D, Manufacturing and Sales

Field of Diseases

With a preferred product portfolio of 13 biological assets capable of continuous development, Tasly Biopharma focuses on the development of biologic drugs in three major therapeutic areas of cardiovascular diseases, oncology and autoimmune diseases, and alimentary tract and metabolism.

We have the new generation of fibrin-specific thrombolytic drug–PUK, available on the market and other products under development such as acute ischemic stroke (AIS) B1140, acute pulmonary embolism (APE) B1448 and PCSK9 monoclonal antibody B1655 for targeted treatment of hypercholesterolemia.

We focus on the development of new drugs such as monoclonal antibodies, bispecific antibodies, oncolytic virus, and immunotherapeutic products, and have the product varieties under development including a fully-human EGFR-targeted monoclonal antibody SY101 for the treatment of advanced colorectal cancer and oncolytic virus product T601 for the treatment of advanced malignant solid tumors.

In response to unfulfilled clinical needs in the field of alimentary tract and metabolism, we are developing products such as B1344 ，for non-alcoholic steatohepatitis (NASH).

By far

We have a product portfolio of 13 biological assets, including one Category I innovative biologic thrombolytic drug PUK on the market, one product in NDA, one product in Phase III clinical trial，two products in Phase II clinical trial, one products in Phase I clinical trial and seven preclinical products. This makes up a preferred product portfolio capable of continuous development to allow more patients worldwide to benefit from high-quality and cost-effective innovative biologic drugs.

13 A product portfolio of 13 biological assets

3 Received 3 fundings under the National Science and Technology Major Project — Major Innovative Drug Development

3 Three Torch Programs, New Product Project, and biomedical industry transformation

An integrated commercial platform covering all life cycles of biological drugs

Mature marketing network

Open biologics R&D platform

The manufacturing capabilities based on the perfusion culture technology

Talent Recruitment

Talent Is The Root Driving Scientific And Technological Innovation

We will build a biopharmaceutical company that continues to innovate in key therapeutic areas. In the process, we will never stop looking for like-minded colleagues to fight and grow together.